Loading
A phase 2 trial of Pamidronate, Thalidomide and Zoledronic acid in Multiple myeloma, run by University of Arkansas, completed.
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide is a phase 2 interventional study registered as NCT00083382 by University of Arkansas, with 83 participants recorded, started 1998-12 and reaching its primary completion in 2014-05. Interventions recorded: Pamidronate, Thalidomide, Zometa. Conditions recorded: Multiple Myeloma.
Linked to the drug Pamidronate because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Shares Pamidronate, Thalidomide, Zoledronic acid, Multiple myeloma and the tag pipeline.
Shares Pamidronate, Multiple myeloma and the tag pipeline.
Shares Zoledronic acid, Multiple myeloma and the tag pipeline.
Shares Smouldering multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Zoledronic acid and the tag pipeline.
Shares Zoledronic acid and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.